Non-Small Cell Lung Cancer Market to Grow with a CAGR of 10.51% through 2030
Increasing
advancements in NSCLC diagnostics and the growing number of clinical trials for
novel therapies, is expected to drive the Global Non-Small Cell Lung Cancer
Market growth in the forecast period, 2026-2030
According to
TechSci Research report, “Non-Small Cell Lung Cancer Market – Global
Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”,
the Global Non-Small Cell Lung Cancer Market stood at USD 19.81 Billion in
2024 and is expected to reach USD 36.13 Billion by 2030 with a CAGR of 10.51% during
the forecast period. The global Non-Small Cell Lung Cancer (NSCLC) market is
expanding as a result of significant advancements in both treatment and
diagnostics. Recent innovations in immunotherapy, particularly immune
checkpoint inhibitors, have provided patients with better treatment options
that show promising survival rates. Alongside immunotherapies, the use of
targeted therapies has gained ground, as they focus on specific genetic
mutations that drive NSCLC growth. For instance, treatments targeting mutations
like KRAS G12C and MET amplification have opened new avenues for personalized
care. Precision medicine is on the rise, with a greater emphasis on tailoring
treatment plans based on genetic biomarkers, which increases the likelihood of
positive outcomes. This approach is complemented by advancements in liquid
biopsy technology, allowing for non-invasive, real-time monitoring of treatment
progress and disease recurrence.
Rising global
healthcare investments and the growing demand for advanced cancer treatments
are pivotal drivers of the NSCLC market. The approval of new therapies and the
expansion of clinical applications for existing drugs have significantly
contributed to the therapeutic landscape. Increased awareness around lung
cancer, supported by various public health campaigns and advocacy groups, is
improving early diagnosis rates, making it easier for healthcare providers to
implement appropriate therapies at an earlier stage. Additionally, the growing
role of artificial intelligence in drug discovery and clinical trial design is
streamlining the process of identifying effective NSCLC treatments.
Growth
opportunities in the NSCLC market are abundant due to the increasing number of
innovative drug candidates entering clinical trials. The growing adoption of
combination therapies, especially those that integrate immunotherapy with
chemotherapy or targeted therapy, is poised to enhance patient survival rates.
Moreover, early diagnosis initiatives and advancements in genetic screening
hold promise for the detection of NSCLC at earlier, more treatable stages.
Collaborations between pharmaceutical companies and healthcare providers to
improve patient access to cutting-edge therapies, particularly in underserved
markets, offer substantial opportunities for growth. These trends are likely to
drive the continued expansion of the NSCLC treatment market in the forecast
period.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Global Non-Small Cell Lung Cancer Market”
The Global Non-Small
Cell Lung Cancer Market is segmented into type, treatment, drug type, end-user,
regional distribution, and company.
Based on the End-User, Hospitals & Clinics emerged as the fastest growing segment in the Global Non-Small Cell Lung Cancer Market during the forecast period. Accurate diagnosis and staging are critical in determining the most appropriate treatment strategy for NSCLC patients. Hospitals and clinics are equipped with state-of-the-art diagnostic tools, including computed tomography (CT) scans, magnetic resonance imaging (MRI), positron emission tomography (PET) scans, and bronchoscopy, among others. These facilities have the expertise to precisely diagnose NSCLC and determine its stage, which is essential for treatment planning. NSCLC treatment often requires a multidisciplinary approach, involving medical oncologists, radiation oncologists, pulmonologists, surgeons, radiologists, and pathologists, among others. Hospitals and clinics provide a collaborative environment where specialists from various disciplines can work together to develop personalized treatment plans tailored to each patient's specific needs. Hospitals and clinics offer a wide range of treatment modalities for NSCLC patients. These include surgery, chemotherapy, radiation therapy, targeted therapies, immunotherapies, and palliative care. Patients can access all these treatment options under one roof, ensuring comprehensive care and convenience. These factors collectively contribute to the growth of this segment.
Based on the Region, Asia-Pacific emerged as the fastest growing region in the Global Non-Small Cell Lung Cancer Market during the forecast period. Factors such as Rising smoking rates and changing lifestyles in some
APAC countries contribute to an increased NSCLC incidence. Many APAC countries
are investing heavily in healthcare infrastructure development, including the
establishment of modern cancer centers and research facilities. As the region's
economies grow, more patients gain access to innovative NSCLC therapies and
treatment options. The region is becoming a hub for clinical trials, attracting
global pharmaceutical companies and researchers, which accelerates the
development of new treatments. Some APAC governments are implementing policies
and programs to improve cancer awareness, early detection, and access to
treatment. Expanding health insurance coverage in APAC countries is making
NSCLC treatments more accessible and affordable for patients.
Major companies
operating in Global Non-Small Cell Lung Cancer Market are:
- Bayar Healthcare AG
- Eli Lilly & Co.
- Biogen Inc
- Merck & Co
- AbbVie Inc
- AstraZeneca PLC
- Novartis AG
- Pfizer Inc
- Avid Bioservices Inc
- Blueprint Medicines Company
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Advancements
in Diagnostics and increasing prevalence are key drivers of the Non-Small Cell
Lung Cancer market. In recent years, The development of innovative treatment
modalities, including targeted therapies and immunotherapies, has expanded the
range of options available to NSCLC patients, boosting market demand. Moreover,
the growing consumer emphasis on preventative healthcare products has enhanced
production and marketing efforts. To meet the demands of the market,
manufacturers are increasingly incorporating cutting-edge technologies with
high production efficiency. Rising consumer acceptance and continuous product
innovation will further ensure the growth of the Non-Small Cell Lung Cancer and
supplements market in the coming years.,” said Mr. Karan Chechi, Research
Director of TechSci Research, a research-based management consulting firm.
“Non-Small Cell Lung
Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
Segmented By Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell
Carcinoma), By Treatment (Chemotherapy, Immunotherapy, Radiation Therapy,
Surgery, Targeted Therapy Drugs), By Drug Class (Angiogenesis Inhibitor,
Epidermal Growth Factor Receptor Blocker, Kinase Inhibitor, Microtubule
Stabilizer, Folate Antimetabolites, PD-1/ PD-L1 Inhibitor), By End-User
(Hospitals & Clinics, Others), By Region and Competition, 2020-2030F”,
has evaluated the future growth potential of Global Non-Small Cell Lung Cancer
Market and provides statistics & information on market size, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Non-Small Cell Lung
Cancer Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York, United
States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com